It collected information about principles of enhanced recovery, clinical elements of the patient pathway, metrics and success factors. It established a website to share information and resources, generated a financial and equality impact evaluation, published an implementation guide, and developed an online reporting tool to support implementation. A lead for enhanced recovery was named in each local health authority to prepare for a programme of spread and adoption across the NHS during the ERAS implementation in the second year of the programme. Hip and knee replacement were the focus of ERAS in musculoskeletal care. ERAS is a complex intervention 2, 3 that focuses on several areas of care across patients' pathways through surgery: pre-operatively (for the patient to be in the best possible condition for surgery); peri-operatively 4 (the patient has the best possible management during and after their operation); post-operatively (the patient experiences the best rehabilitation). The intervention includes provision of information before and after surgery, comprising elements such as making changes around the home, strengthening exercises, and changes to nutrition. For patients in whom it is suitable, ERAS aims to enable earlier return home from hospital with tailored discharge. A greater number of frail older people with complex co-morbid conditions now receive hip/knee replacement surgery. The new ERAS pathways' could specifically benefit these patient groups 5 . There is limited evidence concerning the effectiveness of ERAS programmes 6 , particularly when applied nationwide across a healthcare system with variation in the way hospitals organise enhanced recovery services and it is unclear which way is best. Length of stay (LOS) has been declining prior to the intervention, and we hypothesised that after the implementation of ERAS, this downward secular trend would decline faster. For the outcomes of complications, revision, pain and function, we did not have a specific a-prior hypothesis as it is unclear what impact ERAS would have on these outcomes. Our aim is to see if introduction of the ERAS programme for knee replacement has led to improved patient outcomes: less knee pain and better knee function, fewer surgical complications, fewer revision operations and reduced LOS.
Methods

Study design
We used a natural experimental study design 19 . We evaluated the impact of ERAS on trends before (April 2008eMarch 2009), during (April 2009eMarch 2011) and after the intervention (April 2011eDecember 2016) 20, 21 ( Supplementary Fig. S1 ). The timing of implementation of ERAS varied by trust and was assumed to span the 2 years of the implementation period (April 2009eMarch 2011).
Participants and inclusion criteria
We included only patients receiving elective surgery ( Fig. 1 ) between 1 April 2008, and 31 December 2016. We excluded patients without a concordant date of surgery between the UK National Joint Registry (NJR) and Hospital Episode Statistics (HES) databases.
Further exclusions were made specific to the outcome being analysed. For LOS we excluded patients staying more than 15 days at hospital. Patients with missing data for LOS were excluded. We excluded patients without information on baseline and/or 6-months follow-up for the analysis of change in Oxford knee scores (OKS). However, we used all patients in a sensitivity analysis after imputing missing values. For complications we excluded patients with surgery after June 2016 to guarantee all patients had at least 6-months of follow up. For revision at 5 years we excluded patients receiving surgery after 2011 to ensure all patients had at least 5-years follow up.
Data source
We used the NJR to obtain data on primary knee replacements. NJR contains data on knee replacement surgeries from 149 UK NHS trusts. NJR includes two million patients since 2003, covering 96% and 90% of primary knee replacements and knee revisions, respectively 7 .
Data linkages
Primary operations were linked with HES data which contains records of all inpatient episodes undertaken in NHS trusts in England (125 million each year). Knee replacements were linked to Patient Reported Outcome Measures (PROMs). A cohort of patients undergoing primary total knee replacement (TKR) in England, UK, was retrieved for the period April 2008eDecember 2016.
Outcome measures
We evaluated trends for LOS at hospital for patients undergoing primary TKR. LOS was calculated as the number of days between hospital admission and discharge date. Time points for the trends were monthly mean LOS. We estimated the inpatient cost relating to the index episode using NHS reference costs from 2015/16 8 . We estimated the mean cost per bed day based on the healthcare resource use (HRG) for each patient and their LOS (Appendix 1).
Monthly mean bed-day costs were the unit of analysis for costs trends.
We assessed absolute change in OKS. Patients complete the same questionnaire about their knee pain and function before and 6 months after surgery 9 . Each question is scored between 0 (worse symptoms) and 4 (least symptoms). Scores from these 12 questions are added getting a total score spanning from 0 (worst possible) and 48 (best possible score). We calculated the absolute difference (change) between baseline and 6-month follow-up scores. Higher positive values for OKS change measure represented greater improvement. OKS trends were obtained by calculating the monthly mean OKS change scores. We estimated mean 6-month complication proportions aggregated by month. We defined post-operative complications as one or more events from the following list: stroke (excluding transient ischaemic attack), respiratory infection, acute myocardial infarction, pulmonary embolism/deep vein thrombosis, urinary tract infection, wound disruption, surgical site infection, fracture after implant, complication of prosthesis, neurovascular injury, acute renal failure and blood transfusion (Appendixes 2 and 3).
We evaluated the rate of revision at 5 years by month of primary TKR. We included revisions declared to the NJR registry by the surgeons 10 and revisions reported to HES using codes from Appendix 4. We specified our analysis time in years reporting the rate as number of revisions per 1000 implant-years.
Intervention
Nation-wide ERAS implementation was carried out between April 2009 to March 2011. During the first year the programme focused on identifying best practice, determining clinical elements of the patient pathway, publishing an implementation guide, supporting early adopters of the programme to better understand key factors for implementation and sustainability
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. During the second year ERAS supported local health areas for delivering and commissioning implementation of ERAS.
Potential modifiers
Whether trends in LOS and OKS differed by age (18e59, 60e69, 70e79, 80e84, !85 years) and presence of co-morbidities according to the Charlson classification 12 (none vs one or more comorbidities) (Appendix 5).
Missing data
We used Pearson's c 2 statistic to evaluate missingness for OKS across categories of study period (before, during, and after ERAS), age and presence of co-morbidities. OKS at baseline and 6 months was imputed as a sensitivity analysis. We generated a single imputed dataset using a chained equation across 50 iterations to reach a stationary distribution.
Statistical analysis
We described the trends by calculating monthly outcomes, being means (LOS, bed costs, OKS), proportions (complications), rates (revision), together with their 95% confidence intervals (CI). We estimated a fractional polynomial over the study period and plotted the resulting curve. We used an interrupted time series approach to estimate changes in outcomes during and immediately following the intervention period while controlling for baseline levels and trends. We modelled aggregated data points of each outcome of interest by month using segmented linear regression 13 .
Y t is the mean number of days at hospital in month t for LOS outcome; mean OKS change in month t for the PROMs outcome; mean proportion of complications in month t for the 6-month complications outcome; and mean rate of revisions in month t for the 5-year revision outcome. b 5 estimates the change in the trend in the mean monthly number or rate (depending of outcome) after ERAS ended (i.e., ERAS post-implementation trend).
In preliminary analysis we checked the autocorrelation with the previous month, 2 months … until the previous 12 months using Durbin's alternative test 14 . We estimated linear regression models with NeweyeWest standard errors 15 .
All analyses were conducted using Stata version 13.1 (StataCorp, College Station, Texas). We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline 16 .
Results
Between April 2008 and December 2016 there were 486,579 planned primary TKR (Fig. 1) . 57% of patients were women, the average age was 70 years (SD ± 9 years). Mean body mass index (BMI) pointed to a nutritional status of obesity class I 31.0 kg/m 2 (SD ± 5.5 kg/m 2 )
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. The physical status 18 of patients was mild or fit . Prior to ERAS LOS was already decreasing significantly by À0.032% every month (95% CI: À0.035% to À0.028%) ( Table I ). The rate of reduction in mean LOS declined at a slower rate (À0.016%, i.e., baseline trend e trend change after ERAS) after the intervention period (April 2011ÀDecember 2016).
Although older patients had a longer LOS, the secular trends in decreasing LOS were seen across all age groups (e.g., 5.1 days (95% CI: 4.9À5.4) to 3.3 days (95% CI: 3.1À3.4) in those age 18e59 and 7.7 days (95% CI: 7.2À8.2) to 5.4 days (95% CI: 5.1À5.8) in age !85) (Fig. 3, Supplementary Table S1 ). Secular trends also decreased in patients with and without pre-existing co-morbidity (Fig. 4) . Cost data were estimated for a total of 479,353 patients. The results for mean inpatient bed day cost over time shows a similar trend to that observed for LOS. Overall mean cost of the index hospital episode decreased from £7607 (95% CI: £7511À£7704) in April 2008 to £5276 (95% CI: £5213À£5339) in December 2016 (Fig. 5 ).
OKS change
We excluded 48% of patients with missing information for OKS in the analysis of change in PROMs (Fig. 1) . We found more missing data for OKS change prior to ERAS (88.6%) than in the implementation period or after ERAS (43.0% and 45.0%, respectively) (Supplementary Table S2 ). Supplementary Table S3 shows more patients without data for OKS change than with data in the period prior to ERAS (15.7% and 1.9%, respectively). Tables S5 and S6 ).
The interrupted time-series model for OKS change shows that prior to ERAS OKS change increased by 0.052% (95% CI: À0.044% to 0.148%) every month (Table I ) and in the imputed dataset by 0.053% (95% CI: 0.042%À0.064%) (Supplementary Table S5 ). During ERAS implementation (April 2009ÀMarch 2011) the secular trend slowed down by 0.009 and increased significantly again after ERAS by 0.071.
Complication at 6-months
6884 (1.6%) patients had one or more complications 6 months after TKR. The proportion of complications decreased from 4.1% (95% CI: 3.5À4.8) to 1.7% (95% CI: 1.3À2.0) [ Fig. 2(C) ]. The interrupted time-series model for complications at 6 months shows that prior to ERAS complication proportion decreased by À0.058% every month (95% CI: À0.071% to À0.045%) ( Table I ). The period after the ERAS intervention remained stable.
5-Year revision rates
3917 (2.2%) patients had a knee revision in the following 5 years according to the NJR registry. We found 30 more 5-year revisions using HES giving a total of 3947 (2.2%). Rates of 5-year knee revision per 1000 implant year remained unchanged with a rate of 4.8 per 1000 implants years (95% CI: 3.9À6.0) at risk in April 2008 and 4.8 (95% CI: 3.9e5.9) in December 2011 [ Fig. 2(D) ]. The model for 5-year knee-revision rates shows a significant downward trend of À0.031 per 1000 implants years (95% CI: À0.058 to À0.003) during ERAS implementation (April 2009eMarch 2011) ( Table I ). The trend changed direction by increasing during the post-intervention period (April 2011eDecember 2016) in 0.040 per 1000 implants years (95% CI: 0.021e0.060).
Discussion
Prior to the introduction of ERAS LOS and inpatient bed-day cost were declining. Although LOS and inpatient bed-day cost continued to decrease after ERAS implementation, this was at half the rate of decline. The absolute change in OKS was higher following ERAS implementation, but although significant, it did not reach clinical significance. There was no change in complications, while the 5-year revision trend slightly increases after ERAS. LOS and OKS trends were seen across all age groups, and in those with and without co-morbidity. Reductions in LOS have been achieved without adversely impacting on patient outcomes. However, implementation of ERAS either slowed down or maintained preexisting secular trends.
We know from other UK studies that LOS has been in gradual decline in the years prior to 2008, where Burn et al. found that in 1997 mean LOS for TKR was 18.89 days, and in 2008, before the ERAS intervention, 7.49 days 19 . We expected to observe a steeper trend in the decrease in LOS after the intervention period (2009e2011). Although we did not a-priori know what pattern would be expected prior to ERAS for the other outcomes, we hypothesized that following the intervention, outcomes of patient reported pain and function, complications, and revision surgery should improve. Our assumptions, for this "natural experiment" of the implementation of ERAS, were that this large scale intervention was implemented homogenously across all England NHS trusts spanning this 2-year period. There was already an encouraging trend towards reduction in LOS and improved outcomes that had begun prior to the official ERAS programme. This is likely to reflect early adoption of elements of ERAS methods in some Trusts, prior to the start of the Dates of implementation of ERAS were different among hospitals. How long that implementation could span or actually spanned are not provided in the Department of Health guideline or in the subsequent report 11, 20 . Because of the complexity of the intervention and stakeholders involved this could vary between hospitals. Therefore, our quasi-experimental approach smoothed dissimilarities in times used to adopt the ERAS intervention.
External influencing factors
Our results show trends in outcomes that has been achieved in the context of an increasing strain on NHS funding and hospital budgets. NHS funding growth is much slower than the historical long term trend 21 . There are fewer hospital beds and wards have been closed. For example, the average daily number of occupied beds open overnight for trauma and orthopaedics for England between April and June 2010 was 10,015 while in October to December 2016 was 8770 22 . Conversely, the number of primary knee replacements increased from 74,277 in 2008 to 98,147 in 2016 23 in England. It has been estimated that 118,666 TKRs will take place by the year 2035 24 . Further to this, the complexity of patients has changed over time, with more patients with co-morbidities now receiving surgery. Efficiencies need to be made to meet this demand within existing or lower capacity. An important issue is the high variation in services and practices across hospitals in England.
The Getting It Right First Time (GIRFT) programme aims to reduce discrepancies between hospitals showing diversity in activity volumes, implant choice, and guidelines follow-up 25 . The first GIRFT report was published in 2012, while the improving trends in outcomes in our study are detected since 2008. Although our results of a positive national trend are encouraging, there still remains substantial variation in outcomes between hospital trusts. In 2016, mean LOS varied between a low of 2.2 days to a high of 5.6, and OKS between 12.8 and 22.3 points. Hence although the national picture has improved for patients as a whole, there is still work to be done to reduce and understand unwarranted variations in outcome between individual hospitals. Many studies supporting the implementation of ERAS pathways have been placed in single institutions or rather small trials 26 . Thus, they may not be generalizable to the wider population. Reductions in LOS prior to the official implementation of ERAS may reflect a commitment to improving the cost-effectiveness of this surgery which represents an important expenditure for the NHS 19, 27, 28 .
Reduction in LOS has been reported in systematic reviews and randomised clinical trials comparing patients following an ERAS programme for colorectal and other planned surgeries against those under conventional care 6 . There is variation in the type of ERAS intervention for knee replacement that has been evaluated among previous studies 29e35 that preclude us to make generalizations at a nationwide level. Additionally, these studies were limited to only one hospital or trust. Moreover, they were focused on the comparison of the intervention with traditional management. Our study investigates whether the ERAS pathway has been successfully implemented comparing with a previous period without ERAS, as has been done in other studies 30e32 , but also, and for first time, comparing with the post-intervention period. The decreasing trend in LOS over time was also reflected in the change in estimated average inpatient bed day cost. We found that the majority of episodes in the data had a LOS less than the trim point for the relevant cost HRG. This meant that (assigning the same unit cost to all patients with the same HRG who had a LOS below the trim point) the reduction in LOS within the trim point would not be reflected by a change in the estimated average episode costs. We therefore estimated the true reduction in NHS expenditure by estimating a cost per bed day reflecting the LOS for each patient.
OKS change scores increased across the study period. However, the change of~2e3 points using complete and imputed cases does not reaching the clinically meaningful difference of 5 points suggested within the literature 36 . A review on ERAS in total hip replacement shows that better improvement in pain and function scores could be related to making patients active participants in their recovery and to help them to manage their expectations 28 . A Cochrane review on preoperative education for hip or knee replacement did not find additional benefits over usual care 37 . However, non-significant reduction of pain and better function were reported to be associated with preoperative education.
The 6-month complications were decreasing until the implementation took place. Subsequently, the trend remained steady during the ERAS period and slightly increased following the intervention. Potentially, discharging patients too soon after surgery could increase complications. However, a meta-analysis in colorectal surgery on several ERAS programmes did not find evidence of an increased risk of surgical complications 38 , and found that cardiovascular, pulmonary, and infectious medical complications decreased. Patients with diabetes undergoing hip and knee replacement under ERAS protocols reduce the additional risk for complications otherwise associated with operating patients with diabetes 39 . A limitation is that manipulation under anaesthesia was not considered among the list of 6-month complications. Werner et al. found 4.24% requiring manipulation under anaesthesia by 6 months in a large cohort of patients undergoing TKR (n ¼ 141,016). 4.8% of them had a revision within the following 7 years 40 . 5-year revision rates diminished across the study. It has been an important effort to reduce revision rates because the procedure is more complicated to perform 41 . Surveillance of knee replacement revisions, using joint registries, have long been the main measure of primary surgical success/failure until PROMs were also used to assess outcomes 42 . Revision rates could have declined as a consequence of patient selection for primary surgery 43 .
To inform the list of important outcomes for this study, we conducted a forum with the University of Bristol's Musculoskeletal Research Unit's patient involvement group. Mortality was ranked low by the group in respect of its importance to them, and hence has not been included and remains a limitation of the analysis. We did not included BMI as a potential modifier for trends in LOS and OKS. A slightly higher proportion of obese patients (!35 kg/m 2 )
between 2008 and 2016 (21.4% and 25.3%, respectively) might influence trends for LOS and OKS, respectively. 
Conclusion
Our study shows that trends of improved outcomes of planned TKR slowed down after ERAS. LOS, OKS, complications and revisions are currently better than 10 years ago. LOS has declined substantially over the study period, consistent across all age groups and in people with and without co-morbidity. Nevertheless, declines in LOS were half the initial decline following ERAS implementation. Reductions in LOS have been achieved without adversely impacting on patient outcomes. Patient reported outcomes in respect of pain and function have improved, but did not reach clinical significance. Complication rates remain stable and revision rates decline less than before ERAS implementation. These trends in outcomes have been achieved in the context of reductions in the numbers of available beds/wards/operating theatres, with increasing absolute numbers of patients undergoing TKR year on year and sicker patients over the study time.
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Appendix 1. Cost methods
Objective
We aimed to estimate the trend in National Health Service (NHS) expenditure over time, reflecting the change in length of stay (LOS) observed.
Grouper and reference cost methods
Using Hospital Episode Statistics (HES) data for the same group of patients as for LOS (i.e., excluding those with LOS above 15 days), we generated healthcare resource use group (HRG) classifications for the index episode for each patient using the 2015/16 NHS reference costs grouper [1], which were subsequently used to estimate inpatient costs per patient using NHS reference costs from 2015/16 [2] .
A reduction in LOS within the trim point is therefore not reflected in the cost of the episode, despite there being a true reduction in NHS costs. In order to estimate the mean change in NHS expenditure we therefore estimated an adjusted average bed day cost.
Estimating the adjusted average bed day cost
For each HRG we estimated the average cost per bed day (defined as any part of a day spent in hospital) by dividing the total cost of the index episodes for that HRG by the total number of bed days for that HRG. This generated a single average bed day cost per HRG.
For each patient we estimated the adjusted episode cost by multiplying their LOS (bed days) by the average bed day cost for the HRG that they had been assigned by the NHS reference costs grouper [1] . Therefore, instead of assigning the same unit cost to all patients with the same HRG who had a LOS below the trim point, the adjusted cost differed according to a patient's LOS, even if that LOS was below the trim point for the HRG. Using this method we were able to estimate the average difference in true NHS expenditure as a result of the reduction in LOS over time even when the LOS was below the trim point.
The 2015/16 grouper and reference costs [1,2] were used to estimate costs for all patients in all years, as there are differences in the methodologies used for HRG classification in different cost years [3] . This prevents a like-for-like comparison between years if different groupers and/or costs are used.
Costs were estimated for a total of 517,798 patients. Classification of Diseases and Related Health Problems 10th Revision (ICD-10) that we used to identify complications in the Hospital Episode Statistics (HES) registry Stroke I60.X, "Subarachnoid haemorrhage"; I61.0, "Intracerebral haemorrhage in hemisphere, subcortical"; I61.1, "Intracerebral haemorrhage in hemisphere, cortical"; I61.2, "Intracerebral haemorrhage in hemisphere, unspecified"; I61.3, "Intracerebral haemorrhage in brain stem"; I61.4, "Intracerebral haemorrhage in cerebellum"; I61.5, "Intracerebral haemorrhage, intraventricular"; I61.6, "Intracerebral haemorrhage, multiple localized"; I61.8, "Other intracerebral haemorrhage"; I61.9, "Intracerebral haemorrhage, unspecified"; I63.0, "Cerebral infarction due to thrombosis of precerebral arteries"; I63.1, "Cerebral infarction due to embolism of precerebral arteries"; I63.2, "Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries"; I63.3, "Cerebral infarction due to thrombosis of cerebral arteries"; I63.4, "Cerebral infarction due to embolism of cerebral arteries"; I63.5, "Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries"; I63.6, "Cerebral infarction due to cerebral venous thrombosis, nonpyogenic"; I63.8, "Other cerebral infarction"; I63.9, "Cerebral infarction, unspecified"; and I64.X, "Stroke, not specified as haemorrhage or infarction".
Respiratory infection
J12.X, "Viral pneumonia, not elsewhere classified: bronchopneumonia due to viruses other than influenza viruses"; J13, "Pneumonia due to Streptococcus pneumoniae"; J14, "Pneumonia due to Haemophilus influenzae"; J15.X, "Bacterial pneumonia, not elsewhere classified: bronchopneumonia due to bacteria other than S. pneumoniae and H. influenzae"; J18.0, "Bronchopneumonia, unspecified. Excluding bronchiolitis"; J18.1, "Lobar pneumonia, unspecified"; J18.2, "Hypostatic pneumonia, unspecified"; J18.8, "Other pneumonia, organism unspecified"; J18.9, "Pneumonia, unspecified"; J22, "Unspecified acute lower respiratory infection"; J44.0, "Chronic obstructive pulmonary disease with acute lower respiratory infection. Excluding with influenza"; J44.1, "Chronic obstructive pulmonary disease with acute exacerbation, unspecified"; J69.0, "Pneumonitis due to food and vomit. Excluding Mendelson syndrome"; J69.1, "Pneumonitis due to oils and essences"; J69.8, "Pneumonitis due to other solids and liquids. Pneumonitis due to aspiration of blood"; and J85.1, "Abscess of lung with pneumonia. Excluding with pneumonia due to specified organism". 
Algorithm
One code from procedure type 1 or a combination of one code from procedure type 2 and site for revision were used to identify knee revision. Combination of codes from procedures type 3 and type 1 or procedure type 3, type 2 and site of surgery identified knee revision after a primary knee unicompartmental replacement (UKR).
Code Procedure
Procedure type 1 W40.0 Conversion from previous cemented total prosthetic replacement of knee joint W40. 2 Conversion to total prosthetic replacement of knee joint using cement W40. 3 Revision of total prosthetic replacement of knee joint using cement W40. 4 Revision of one component of total prosthetic replacement of knee joint using cement W41.0
Conversion from previous uncemented total prosthetic replacement of knee joint W41. 2 Conversion to total prosthetic replacement of knee joint not using cement W41. 3 Revision of total prosthetic replacement of knee joint not using cement W41. 4 Revision of one component of total prosthetic replacement of knee joint not using cement W42.0
Conversion from previous total prosthetic replacement of knee joint not elsewhere specified (NEC) W42. 2 Conversion to total prosthetic replacement of knee joint NEC W42. 3 Revision of total prosthetic replacement of knee joint NEC W42. 4 Attention to total prosthetic replacement of knee joint NEC W42. 5 Revision of one component of total prosthetic replacement of knee joint NEC W42. 6 Arthrolysis of total prosthetic replacement of knee joint W58.0
Conversion from previous resurfacing arthroplasty of joint O18.0
Conversion from previous hybrid prosthetic replacement of knee joint using cement O18. 2 Conversion to hybrid prosthetic replacement of knee joint using cement O18. 3 Revision of hybrid prosthetic replacement of knee joint using cement O18. 4 Attention to hybrid prosthetic replacement of knee joint using cement Procedure type 2 W52.0
Conversion from previous cemented prosthetic replacement of articulation of bone NEC W52. 2 Conversion to prosthetic replacement of articulation of bone using cement NEC W52. 3 Revision of prosthetic replacement of articulation of bone using cement NEC W53.0
Conversion from previous uncemented prosthetic replacement of articulation of bone NEC W53. 2 Conversion to prosthetic replacement of articulation of bone not using cement NEC W53. 3 Revision of prosthetic replacement of articulation of bone not using cement NEC W54.0
Conversion from previous prosthetic replacement of articulation of bone NEC W54. 2 Conversion to prosthetic replacement of articulation of bone NEC W54. 3 Revision of prosthetic replacement of articulation of bone NEC W54. 4 Attention to prosthetic replacement of articulation of bone NEC W55. 3 Conversion to prosthetic interposition arthroplasty of joint W56. 4 Conversion to interposition arthroplasty of joint NEC W57. 4 Conversion to excision arthroplasty of joint W60. 3 Conversion to arthrodesis and extra-articular bone graft NEC W61. 3 Conversion to arthrodesis and articular bone graft NEC W64.1
Conversion to arthrodesis and internal fixation NEC W64. 2 Conversion to arthrodesis and external fixation NEC Site for revision Z76. 5 Lower end of femur NEC Z77. 4 Upper end of tibia NEC Z78.7 Patella Z84. 4 Patellofemoral joint Z84. 5 Tibiofemoral joint Z84. 6 Knee joint Procedure type 3 W40.1
Primary total prosthetic replacement of knee joint using cement W40. 8 Other specified total prosthetic replacement of knee joint using cement W40. 9 Unspecified total prosthetic replacement of knee joint using cement W41.1
Primary total prosthetic replacement of knee joint not using cement W41. 8 Other specified total prosthetic replacement of knee joint not using cement W41. 9 Unspecified total prosthetic replacement of knee joint not using cement W42.1
Primary total prosthetic replacement of knee joint NEC W42. 8 Other specified other total prosthetic replacement of knee joint W42. 9 Unspecified other total prosthetic replacement of knee joint O18.1
Primary hybrid prosthetic replacement of knee joint using cement O18. 8 Other specified hybrid prosthetic replacement of knee joint using cement O18. 9 Unspecified hybrid prosthetic replacement of knee joint using cement
